FDA to Clear Path for Drugs Aimed at Cancer-Causing Genes
- New policies will help facilitate ‘tumor-agnostic’ treatments
- FDA Commissioner Gottlieb talks about push before Senate panel
Leukemia cells
Soruce: Smith Collection/Gado/Getty ImagesThis article is for subscribers only.
For years, doctors have identified cancers by the affected body part: lung, breast, kidney. Now, in a long-awaited move, U.S. drug regulators will simplify the approval of treatments targeting specific gene mutations that can spur tumors in a variety of organs.
The Food and Drug Administration will soon announce a plan to update agency policies and facilitate the approval of critically needed drugs, including so-called “tumor-agnostic” therapies that target cancer-linked DNA, according to FDA Commissioner Scott Gottlieb.